STIM1 and cardiac hypertrophy: The chronic treatment with the cholinesterase inhibitor, pyridostigmine, after AAB or TAC in rats or mice, respectively, attenuates cardiac hypertrophy and improves cardiac contractile performance and rhythmic activity by suppressing the interaction of Orai1/STIM1 [80] or diminishing pathologically enhanced STIM1 expression and SOCE in hypertrophied myocytes [71].